FDA advisers weigh in on BPC-157 and six other peptides
A federal advisory panel looked at whether pharmacies should be allowed to make seven popular peptides. Here’s what happened, and what it does and doesn’t mean.
At a glance
- When
- July 23–24, 2026
- Who
- The FDA’s Pharmacy Compounding Advisory Committee
- Peptides reviewed
- BPC-157, KPV, TB-500, MOTS-c, DSIP (emideltide), Semax and Epitalon
- Purpose
- Consideration for the Section 503A compounding ingredients list
- Is it approval?
- No. Advisory recommendations are non-binding; FDA makes the decision
The research, explained
Compounding pharmacies make medicines for individual patients from raw ingredients, for example when someone needs a strength or form that isn’t sold. In the US they can only use raw ingredients that meet certain rules, such as being part of an approved medicine or being on an FDA list. While the FDA reviews newly nominated ingredients, it keeps interim lists, and “Category 1” ingredients can be used in the meantime.
In July 2026 the FDA asked its expert advisers about seven peptides that people had nominated for that list. On July 23 the panel looked at BPC-157 (for ulcerative colitis, a bowel disease), KPV (for wound healing and inflammation), TB-500 (for wound healing) and MOTS-c (for obesity and osteoporosis). On July 24 it looked at DSIP (for opioid withdrawal, insomnia and narcolepsy), Semax (for stroke-related conditions, migraine and facial nerve pain) and Epitalon (for insomnia).
The official agenda and meeting recordings document the substances and proposed uses under discussion. This summary does not infer a final regulatory decision from an advisory meeting.
Advisory committee recommendations are non-binding. Inclusion on the compounding list and approval of a finished medicine are separate regulatory decisions.
For what is actually known about these peptides in people, read BPC-157’s human evidence, Semax and Selank, Epitalon and DSIP.
What does this mean?
If the FDA follows the panel, licensed pharmacies could one day prepare BPC-157 for individual patients with a prescription. That would bring some quality control to a peptide that is mostly sold online today without any oversight.
What don’t we know yet?
Permission to compound is not the same as approval as a medicine. Even then, there would still be no large human trials showing that BPC-157 works or is safe.
Watch and learn
Watch the original meetings discussed in the article. The research lesson helps distinguish a regulatory discussion from a clinical safety or effectiveness result.
U.S. Food and Drug Administration
FDA peptide compounding meeting: July 23, 2026
Full meeting covering BPC-157, KPV, TB-500 and MOTS-c. Advisory discussion is not drug approval.
Official FDA advisory committee recording
Official regulatory recording
The original July 23, 2026 FDA discussion of BPC-157, KPV, TB-500 and MOTS-c; it documents an advisory review.
U.S. Food and Drug Administration
FDA peptide compounding meeting: July 24, 2026
Full meeting covering DSIP (emideltide), Semax and Epitalon. Advisory discussion is not drug approval.
Official FDA advisory committee recording
Official regulatory recording
The original July 24, 2026 FDA discussion of DSIP, Semax and Epitalon; it documents an advisory review.
National Institute of Mental Health
Clinical research: risks and benefits
Why an experimental treatment can involve uncertainty even when its scientific rationale sounds promising.
NIMH · US National Institutes of Health
Research skills
Helps you judge the study design or uncertainty in BPC-157, KPV, TB-500 research; it is not a trial of the compound.
Sources and references
- July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeUS Food and Drug Administration
- Bulk drug substances nominated for compounding under Section 503AUS Food and Drug Administration · updated May 14, 2026 (PDF)
VETUD Learn explains published research in plain language. It is general information, not medical advice. Talk to a doctor before starting, stopping or changing any treatment.
In the research shop
Check the catalog for related laboratory research materials. These products are separate from the approved medicines and clinical trial formulations discussed here.
Checking regional availability…
